CompanyLocationDateAmt. (M)Details

Adnexus TherapeuticsWaltham, Mass.8/9$15.5Adnexus raised $15.5M in a Series C led by HBM BioVentures Ltd.; it included investments from Atlas Venture, Flagship Ventures, Polaris Venture Partners and Venrock
Aegera Therapeutics Inc.Montreal8/8NDAegera closed its Series C financing, which raised $14M in equity and up to $7M in venture debt last November; the combination of Series C equity, debt and funding gained through an acquisition was as much as $25M
Agendia BVAmsterdam, the




Agendia raised $34M in a fourth financing round; investors were ING, Van Herk Biotech BV, Gilde Healthcare Partners BV and Global Life Science Ventures
AM-Pharma BVBunnik, the Netherlands8/6€2.5 ($3.4)AM-Pharma raised $3.4M from existing investors Forbion Capital Partners and Inventages Venture Capital in the first tranche of a Series C financing
Aquapharm BioDiscovery Ltd.London8/15**£4 ($8)Aquapharm raised $8M in its first round led by Aescap Ventures and the venture arm of Tate and Lyle plc; other investors were regional development agencies and Nesta Investments
Azur Pharma Ltd.Dublin, Ireland8/7$48Azur completed a $48M private placement arranged through Davy Corporate Finance Ltd.
BioMarck Pharmaceuticals Ltd.Research TrianglePark, N.C.8/8$4BioMarck raised $4M in a private financing


Princeton, N.J.8/2$10Celator closed a $10M private equity round, representing a follow-on investment from principal investors Domain Associates LLC, Quaker Bio-Ventures, TL Ventures, Ventures West Management Inc., GrowthWorks Capital Ltd., the Business Development Bank of Canada and Hearthstone Investment Ltd.
Celltran Ltd.Sheffield, UK8/22**£1 ($1.98)Celltran raised $1.98M in a round led by Yorkshire Fund Managers; other investors were South Yorkshire Investment Fund, Innogenetics NV, Biofusion plc, White Rose Technology Seed-corn Fund and PUK Ventures
Celsense Inc., Glucose Sensing Technologies LLC and Falcon Genomics Inc.Pittsburgh8/14$0.35The companies raised a total of $350,000 through the Pittsburgh Life Sciences Greenhouse
Edison Pharmaceuticals Inc.San Jose, Calif.8/2$4.25Edison closed a $4.25M Series B preferred stock offering led by Carl Berg, of Berg & Berg Enterprises LLC; new investors included John W. Marriott III, president and CEO of JWM LP, and JWM Family Enterprises
EKR Therapeutics Inc.Cedar Knolls, N.J.8/15$13EKR raised $13M in a Series C round led by Quaker BioVentures; other investors are Merrill Lynch Capital Healthcare Finance Group, Garden State Life Sciences Venture Fund, NewSpring Capital and ESP Equity Partners
Inotek Pharmaceuticals Corp.Beverly, Mass.8/24$19.3Inotek raised $19.3M in a Series C round, which included investments from Hercules Technology Growth Capital, Meditor Capital Management and Mitsubishi UFJ Capital, as well as Care Capital LLC, La Caisse de Depot et placement du Quebec, MedImmune Ventures, Pitango Venture Capital and Rho Ventures
IntelliPharma-Ceutics Ltd.Toronto8/2NDPar Pharmaceutical Cos. Inc. made a significant equity investment in the company, acquiring a 4.2% interest in the company
KineMed Inc.Emeryville, Calif.8/3$15KineMed completed a $15M convertible note offering led by a direct investment from Stanford Financial Group and joined by existing investors from previous financing rounds; Ledge-mont Capital served as placement agent
Molecular Partners AGSchlieren, Switzerland8/14CHF18.5 ($15.3)Molecular Partners raised $15.3M in a Series A round led by Index Ventures; other participants were BB Biotech Ventures, Johnson & Johnson Development Corp. and Endeavour Vision
Nereus Pharmaceuticals Inc.San Diego8/9$45Nereus raised $45M in a Series D-2 financing round led by BankInvest Biomedical Venture; other investors were Roche Venture Fund, Astellas Venture Management, Boston Life Science Venture Corp., Taiwan Global Biofund and Eminent Venture Capital Corp.
NeurAxon Inc.Waltham, Mass.8/20$32NeurAxon raised $32M in a Series B round led by Delphi Ventures and OrbiMed Advisors LLC; other investors were BDC Venture Capital, Genesys Capital Partners, H.I.G. Ventures, Neuro-Ventures Fund, Ventures West Capital Ltd. and CEO Lawrence Bloch
Neuromed Pharmaceuticals Inc.Vancouver, British Columbia8/21$53.3Neuromed closed a $53.3M Series E financing; investors were MPM Capital, James Richardson & Sons Ltd., Neuro Discovery LP, GrowthWorks Capital, BDC Venture Capital, Canadian Medical Discoveries Fund Inc. and the Royal Bank of Canada
Novacta Biosystems Ltd.Welwyn Garden City, UK8/3€0.6($0.827)Novacta completed an investment round from new investors, including Esperante, and existing shareholders Westgate Hall, GEIF Ventures and Oxford Technology 4 VCT
OncoVista Inc.San Antonio8/30$6.8OncoVista raised $6.8M selling 970,712 units consisting of stock and warrants; investors were Wexford Capital LLC, CAMOFI Master LDC, Bristol Investment Fund Ltd. and other institutional and qualified investors; Maxim Group LLC was exclusive placement agent for the deal
OphthotechPrinceton, N.J.8/13$36Ophthotech raised $36M in a Series A round led by SV Life Sciences, with participation from HBM BioVentures and Novo A/S
Pevion Biotech AGBern, Switzerland8/10CHF35 ($29.3)Pevion raised $29.3M in a Series A round led by BZ Bank AG; other participants included BB Biotech Ventures II LP, which is advised by Bellvue Asset Management AG and CC Private Equity Partners Ltd.
Presidio Pharmaceuticals Inc.San Francisco8/29$26Presidio raised $26M in a Series B round; investors were Baker Brothers Investments, Bay City Capital, Ventures West Capital and Nexus Medical Partners, as well as Sagamore Bioventures, George Rathmann Fund and Peninsula Overview Partners
Proteros biostructures GmbHMartinsried, Germany8/22€1 ($1.4)Proteros received a $1.4M investment from BayBG Bayerische Beteiligungsgesellschaft mbH
Tobira TherapeuticsPrinceton, N.J.8/2$31Tobira raised $31M in a Series A round led by Domain Associates and Frazier Healthcare Ventures; Montreux Equity Partners and Canaan Partners also participated
Topigen Pharmaceuticals Inc.Montreal8/15C$26


Topigen closed a Series C round, raising $24.7M; BDC Venture Capital led the first close, with participation from Desjardins Venture Capital, Caisse de depot et placement du Quebec, 12C2/BIO 2000 and Lothian Partners 27 (sarl) SICAR, as well as MMV Financial Inc. and NovaQuest

Currency conversions are based on exchange rates at the time of the deal.
** Denotes the date the item ran in BioWorld International.
ND = Not disclosed.

No Comments